Amylyx Pharmaceuticals, Inc. reported $0 of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $0 (to Q4 2025). Net income: −$152M, trailing twelve months to Q2 2026. Free cash flow: −$123M, trailing twelve months to Q4 2025. EPS: −$1.41, trailing twelve months to Q2 2026.

AMLXAmylyx Pharmaceuticals, Inc.

Healthcare

$28.14+111% 1Y

$28.14

$11.3852 weeks$39.67

AMLX as reported

Amylyx Pharmaceuticals, Inc. reported $0 of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed.

Revenue, trailing twelve months · to Q4 2025 · every figure below is as filed, with no scoring applied

Net income: −$152M
Net income · −19% year on year · trailing twelve months to Q2 2026
Free cash flow: −$123M
Free cash flow · trailing twelve months to Q4 2025
EPS: −$1.41
EPS · −43% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for AMLX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$0	n/a	Q4 2025
Net income	−$152M	−19%	Q2 2026
EPS	−$1.41	−43%	Q2 2026
Gross margin	92%	n/a	Q3 2023 · 11 quarters behind
Operating margin	−42%	n/a	Q3 2023 · 11 quarters behind
Net margin	−38%	n/a	Q3 2023 · 11 quarters behind
ROE	−53%	n/a	Q2 2026
ROA	−48%	n/a	Q2 2026
Free cash flow	−$123M	n/a	Q4 2025

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.